Concepedia
Statistics
Publications
4
Citations
107
H-Index
Active since
2017
Affiliations
Freeman Hospital(Current)
University College London
Sarah Cannon Research Institute
Royal Marsden NHS Foundation Trust
Institute of Cancer Research
Noor Md Haris is an author at Freeman Hospital specializing in pharmacology, oncology, and toxicity management.
Publications per year
2017–2019
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Elizabeth Ruth Plummer, Rebecca Kristeleit, Elena Cojocaru et al. · Journal of Clinical Oncology · 2019 · 31 citations
Pharmacy, Oncology, Pharmacology +13
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
Johann S. de Bono, David S.P. Tan, Reece Caldwell et al. · Journal of Clinical Oncology · 2019 · 30 citations
Medicine, Oncology, Pharmacology +13
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke, Nicola Steele, Hendrik‐Tobias Arkenau et al. · British Journal of Cancer · 2017 · 28 citations · Full text
Pharmacy, Oncology, Pharmacology +17
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
Yvette Drew, Rebecca Kristeleit, Ana Oaknin et al. · The Oncologist · 2019 · 18 citations · Full text
1–4 of 4